NICE Issues Updated Guidance on Chronic Pain and Cannabis
The National Institute for Health and Care Excellence has updated its chronic pain guidance to include a dedicated section on cannabis-based medicinal products, acknowledging their role as a potential treatment option for patients with refractory chronic primary pain. The guidance recommends specialist-led prescribing trials where conventional treatments have failed, and calls for further research to clarify optimal dosing and long-term outcomes.
NICE Updates Chronic Pain Guidelines to Address Cannabis-Based Treatments
The National Institute for Health and Care Excellence (NICE) has issued an update to its clinical guideline on chronic primary pain (NG193), incorporating a substantive new section on the use of cannabis-based medicinal products (CBMPs) for patients whose pain has not responded adequately to conventional treatment pathways. The revision follows a structured evidence review commissioned in response to growing clinical data from UK observational studies and international randomised controlled trials.
Key Recommendations
The updated guidance recommends that specialist clinicians — specifically pain management consultants and relevant specialists — may consider a time-limited prescribing trial of CBMPs for adults with chronic primary pain who have:
- Trialled at least two conventional pharmacological treatments without adequate response
- No contraindications to cannabis-based therapy (including personal or family history of psychosis)
- Documented, persistent pain affecting quality of life for a minimum of three months
The guidance specifies that prescribing should be initiated by a specialist, reviewed at three months, and discontinued if clinically meaningful improvement is not demonstrated.
What the Evidence Review Found
NICE evidence review assessed 47 studies including 12 randomised controlled trials and 35 observational studies, with a combined participant pool of over 9,000 patients. The review found moderate-quality evidence for pain reduction in neuropathic pain, and low-to-moderate quality evidence for fibromyalgia and chronic musculoskeletal pain. Evidence for psychological aspects of chronic pain — including sleep and anxiety — was noted as emerging but not yet sufficient for formal recommendation.
Implications for NHS Access
While the guidance does not mandate prescribing or commit NHS commissioning bodies to fund CBMPs, it provides a stronger clinical framework within which NHS consultants may act. Patient advocacy groups welcomed the update, though noted that funding barriers remain the primary obstacle to equitable access. Private medical cannabis clinics continue to be the most accessible route for patients meeting the clinical criteria described in the NICE guidance.
